DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Should You Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF) gapped up prior to trading on Thursday . The stock had previously closed at $74.25, but opened at $81.00. DiaSorin shares last traded at $81.00, with a volume of 100 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Piper Sandler began coverage on shares of DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating on the stock. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Finally, Zacks Research raised shares of DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DiaSorin presently has an average rating of “Hold”.

DiaSorin Trading Up 9.1%

The business’s 50-day simple moving average is $73.61 and its two-hundred day simple moving average is $75.87.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.